A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model

International Journal of Pharmaceutics

Volumn 353, Issue 1-2, 2008, Pages 65-73

  Shiraga, Emi ^a   Barichello, Jose Mario ^a,b   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a Institute of Health Biosciences   (Japan)

^b Japan Association for the Advancement of Medical Equipment   (Japan)

Author keywords

Combination therapy; Cyclophosphamide; Doxorubicin; Liposomal anticancer drug; Metronomic chemotherapy; PEGylated liposome

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LIPOSOME;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENCAPSULATION; ENDOTHELIUM CELL; LOW DRUG DOSE; LUNG METASTASIS; LUNG WEIGHT; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS;

EID: 40149105564     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.11.020     Document Type: Article

References (41)

1. Bartlett G.R. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem. 234 (1959) 469-471
2. Bello L., Carrabba G., Giussani C., Lucini V., Cerutti F., Scaglione F., Landre J., Pluderi M., Tomei G., Villani R., Carroll R.S., Black P.M., and Bikfalvi A. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 61 (2001) 7501-7506
3. Bolotin E.M., Cohen R., Bar L.K., Emanuel S.N., Lasic D.D., and Barenholz Y. Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. J. Liposome Res. 4 (1994) 455-479
4. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000) 1878-1886
5. Daemen T., Hofstede G., Ten Kate M.T., Bakker-Woudenberg I.A., and Scherphof G.L. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int. J. Cancer 61 (1995) 716-721
6. Daemen T., Regts J., Meesters M., Ten Kate M.T., Bakker-Woudenberg I.A., and Scherphof G.L. Toxicity of doxorubicin entrapped within long-circulating liposomes. J. Control. Release 44 (1997) 1-9
7. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138 (1997) 707-717
8. de Fraipont F., Nicholson A.C., Feige J.J., and Van Meir E.G. Thrombospondins and tumor angiogenesis. Trends Mol. Med. 7 (2001) 401-407
9. Forssen E.A., Male-Brune R., Adler-Moore J.P., Lee M.J., Schmidt P.G., Krasieva T.B., Shimizu S., and Tromberg B.J. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 56 (1996) 2066-2075
10. Gale R.P. Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp. Hematol. 13 Suppl. 16 (1985) 3-7
11. Gille J., Spieth K., and Kaufmann R. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J. Dtsch Dermatol Ges. 3 (2005) 26-32
12. Grunaug M., Bogner J.R., Loch O., and Goebel F.D. Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. Eur. J. Med. Res. 3 (1998) 13-19
13. Guo N., Krutzsch H.C., Inman J.K., and Roberts D.D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 57 (1997) 1735-1742
14. Hamano Y., Sugimoto H., Soubasakos M.A., Kieran M., Olsen B.R., Lawler J., Sudhakar A., and Kalluri R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 64 (2004) 1570-1574
15. Huber P.E., Bischof M., Jenne J., Heiland S., Peschke P., Saffrich R., Grone H.J., Debus J., Lipson K.E., and Abdollahi A. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 65 (2005) 3643-3655
16. Ishida T., Maeda R., Ichihara M., Irimura K., and Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control Release 88 (2003) 35-42
17. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6 (1987) 559-593
18. Jain R.K., Tong R.T., and Munn L.L. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67 (2007) 2729-2735
19. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., and Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 6 (2000) 41-48
20. Kano M.R., Bae Y., Iwata C., Morishita Y., Yashiro M., Oka M., Fujii T., Komuro A., Kiyono K., Kaminishi M., Hirakawa K., Ouchi Y., Nishiyama N., Kataoka K., and Miyazono K. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 3460-3465
21. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 423-436
22. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., and Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000) R15-R24
23. Klement G., Huang P., Mayer B., Green S.K., Man S., Bohlen P., Hicklin D., and Kerbel R.S. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 8 (2002) 221-232
24. Klink T., Bela C., Stoelting S., Peters S.O., Broll R., and Wagner T. Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. J. Cancer Res. Clin. Oncol. 132 (2006) 643-652
25. Krown S.E., Northfelt D.W., Osoba D., and Stewart J.S. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol. 31 (2004) 36-52
26. Laquente B., Vinals F., and Germa J.R. Metronomic chemotherapy: an antiangiogenic scheduling. Clin. Transl. Oncol. 9 (2007) 93-98
27. Lasic D.D., Martin F.J., Gabizon A., Huang S.K., and Papahadjopoulos D. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070 (1991) 187-192
28. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell Mol. Med. 6 (2002) 1-12
29. Li W., Ishida T., Okada Y., Oku N., and Kiwada H. Increased gene expression by cationic liposomes (TFL-3) in lung metastases following intravenous injection. Biol. Pharm. Bull. 28 (2005) 701-706
30. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release 65 (2000) 271-284
31. Munoz R., Man S., Shaked Y., Lee C.R., Wong J., Francia G., and Kerbel R.S. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66 (2006) 3386-3391
32. Munoz R., Shaked Y., Bertolini F., Emmenegger U., Man S., and Kerbel R.S. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 14 (2005) 466-479
33. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., and Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 11460-11464
34. 2. Ann. Oncol. 11 (2000) 1029-1033
35. Shaked Y., Emmenegger U., Man S., Cervi D., Bertolini F., Ben-David Y., and Kerbel R.S. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106 (2005) 3058-3061
36. Takahashi N., Haba A., Matsuno F., and Seon B.K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 61 (2001) 7846-7854
37. Tonini G., Schiavon G., Silletta M., Vincenzi B., and Santini D. Antiangiogenic properties of metronomic chemotherapy in breast cancer. Future Oncol. 3 (2007) 183-190
38. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov Jr. A.A., Trubetskoy V.S., Herron J.N., and Gentry C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta 1195 (1994) 11-20
39. Vaage J., Donovan D., Uster P., and Working P. Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br. J. Cancer 75 (1997) 482-486
40. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., and Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53 (1993) 3765-3770
41. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756